Immuron Ltd Adr Stock Today
| IMRN Stock | USD 0.80 0.04 5.26% |
PerformanceWeakest
| Odds Of DistressLow
|
Immuron is selling at 0.8 as of the 3rd of January 2026; that is 5.26% increase since the beginning of the trading day. The stock's open price was 0.76. Immuron has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 4th of November 2025 and ending today, the 3rd of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of June 2017 | Category Healthcare | Classification Health Care |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia. The company has 8.08 M outstanding shares of which 34.03 K shares are currently shorted by private and institutional investors with about 0.03 trading days to cover. More on Immuron Ltd ADR
Moving against Immuron Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Immuron Stock Highlights
| CEO | Jerry Kanellos | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsImmuron can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immuron's financial leverage. It provides some insight into what part of Immuron's total assets is financed by creditors.
| |||||
Immuron Ltd ADR (IMRN) is traded on NASDAQ Exchange in USA and employs 7 people. Immuron is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.69 M. Immuron Ltd ADR conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.08 M outstanding shares of which 34.03 K shares are currently shorted by private and institutional investors with about 0.03 trading days to cover.
Immuron Ltd ADR currently holds about 22.11 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.88, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Immuron Probability Of Bankruptcy
Ownership AllocationRoughly 99.21 (percent) of Immuron outstanding shares are held by general public with 0.79 pct. by outside corporations.
Check Immuron Ownership Details
Immuron Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2025-06-30 | 16.3 K | |
| Rhumbline Advisers | 2025-06-30 | 5.9 K | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 700 | |
| Bnp Paribas Arbitrage, Sa | 2025-06-30 | 100.0 | |
| Sbi Securities Co Ltd | 2025-06-30 | 10.0 | |
| Wells Fargo & Co | 2025-06-30 | 0.0 |
Immuron Historical Income Statement
Immuron Stock Against Markets
Immuron Corporate Management
| CPA CPA | Chief Officer | Profile | |
| BBus CA | CFO Sec | Profile | |
| Dan Peres | Chief Officer | Profile | |
| Flavio Palumbo | Chief Officer | Profile | |
| David Lyon | Head Marketing | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immuron Ltd ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immuron. If investors know Immuron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immuron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.61) | Revenue Per Share | Quarterly Revenue Growth 0.293 | Return On Assets | Return On Equity |
The market value of Immuron Ltd ADR is measured differently than its book value, which is the value of Immuron that is recorded on the company's balance sheet. Investors also form their own opinion of Immuron's value that differs from its market value or its book value, called intrinsic value, which is Immuron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immuron's market value can be influenced by many factors that don't directly affect Immuron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immuron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immuron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immuron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.